Advanced search
Publication Cover
Cancer Investigation Volume 20, 2002 - Issue 5-6
Submit an article Journal homepage
5
Views
0
CrossRef citations to date
0
Altmetric
Original

Estramustine Plus a Taxane for Advanced Prostate Cancer: The New Standard Therapy?

Matthew I. Milowsky Department of Medicine, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, 525 E, 68th Street, New York, NY, 10021, U.S.A.
, M.D. &
David M. Nanus Department of Medicine, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, 525 E, 68th Street, New York, NY, 10021, U.S.A.
, M.D.
Pages 849-850 | Published online: 17 Jul 2002

REFERENCES

  • Yagoda A., Petrylak D. Cytotoxic Chemotherapy for Advanced Hormone-Resistant Prostate Cancer. Cancer 1993; 71: 1098–1109
  • Roth B.J., Yeap B.Y., Wilding G., Kasimis B., McLeod D., Loehrer P.J. Taxol in Advanced Hormone-Refractory Carcinoma of the Prostate. A Phase II Trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72: 2457–2460
  • Trivedi C., Redman B., Flaherty L.E., Kucuk O., Du W., Heilbrun L.K., et al. Weekly 1-Hour Infusion of Paclitaxel. Clinical Feasibility and Efficacy in Patients with Hormone-Refractory Prostate Carcinoma. Cancer 2000; 89: 431–436
  • Hudes G.R., Nathan F., Khater C., Haas N., Cornfield M., Giantonio B., et al. Phase II Trial of 96-Hour Paclitaxel Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Cancer. J. Clin. Oncol. 1997; 15: 3156–3163
  • Leitner, S. P.; Scoppetuelo, M.; Kanowitz, J. M.; Lowry, P. A.; Clyde, J. Phase II Trial of Weekly One Hour Paclitaxel (T) Plus Oral Estramustine (E) Taken the Day Before, of, and After Paclitaxel in Patients (Pts) with Metastatic Hormone Refractory Prostate Cancer (HRPC). ASCO Proc., 1999; Abstract #1331.
  • Haas, N.; Garay, C.; Roth, B.; Babb, J.; Rogatko, A.; Entmacher, M.; Weinstein, A.; Minitti, C.; Finch, D.; Yeslow, G.; Gillon, T.; Hudes, G. Weekly Pacliatxel by 3-Hour Infusion Plus Oral Estramustine (EMP) in Metastatic Hormone Refractory Prostate Cancer (HRPC). ASCO Proc. 1999, Abstract #1311.
  • Singh, H.; Ferrari, A. C.; Bednar, M. E.; Chachoua, A.; Rosenthal, M.; Muggia, F. Weekly Pacliatxel and High Dose Oral Estramustine in Hormone Refractory Prostate Cancer. ASCO Proc., 2000; Abstract #1494.
  • Smith D.C., Esper P., Strawderman M., Redman B., Pienta K.J. Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer. J. Clin. Oncol. 1999; 17: 1664–1671
  • Lee, M.; Hagan, J.; Brundage, D.; Swenson, K.; Deshler, A.; Flynn, P. A Pilot Study of Mitoxantrone, Estramustine, Paclitaxel and Hydrocortisone (METH) in Patients with Hormone Refractory Prostate Cancer. ASCO Proc., 2000; Abstract #1462.
  • Kelly W.K., Curley T., Slovin S., Heller G., McCaffrey J., Bajorin D., et al. Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients with Advanced Prostate Cancer. J. Clin. Oncol. 2001; 19: 44–53
  • Petrylak D.P. Docetaxel (Taxotere) in Hormone-Refractory Prostate Cancer. Semin. Oncol. 2000; 27: 24–29
  • Hussain M., Petrylak D., Fisher E., Tangen C., Crawford D. Docetaxel (Taxotere) and Estramustine Versus Mitoxantrone and Prednisone for Hormone-Refractory Prostate Cancer: Scientific Basis and Design of Southwest Oncology Group Study 9916. Semin. Oncol. 1999; 26: 55–60
  • Kuzel T.M., Kies M.S., Wu N., Hsieh Y.-C., Rademaker A.W. Phase I Trial of Oral Estramustine and 3-hr Infusional Paclitaxel for the Treatment of Hormone Refractory Prostate Cancer. Cancer Inv. 2002; 20: 634–643

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.